Investigators from University of Texas Health Science Center Houston Target Breast Cancer (Dual Inhibition of the Trka and Jak2 Pathways Using Entrectinib and Pacritinib Suppresses the Growth and Metastasis of Her2-positive and Triple-negative...).

Předmět:	HER2 positive breast cancer TRIPLE-negative breast cancer BREAST cancer CANCER stem cells REPORTERS & reporting
Zdroj:	Women's Health Weekly; 8/16/2024, p505-505, 1p
Abstrakt:	Researchers from the University of Texas Health Science Center in Houston have published a new report on the treatment of HER2-positive and triple-negative breast cancers. These types of breast cancer are difficult to treat and have poor prognoses. The researchers found that a combination of FDA-approved TrkA inhibitors and JAK2 inhibitors effectively inhibited the growth of breast cancer cells in vitro and in mouse models. This study provides preclinical evidence for future clinical evaluations of this treatment approach. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu